← All trials
NCT04659239
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Sep 30, 2021
- Completion date
- Mar 31, 2022
- First posted
- Dec 9, 2020
- Last posted
- Dec 9, 2020
- Enrollment
- 34020
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Chinese Academy of Medical SciencesReponsible party - principal investigator
- CEMEC Pesquisa ClinicaOverall official - principal investigator
- Hospital Sungai BulohOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.